Research advances in hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia
ZHU Si-mei
YANG Han-yue
WANG Jian-tao
Abstract：Chronic kidney disease (CKD) is a long-term progressive disease that is characterized by increasing loss of kidney function that can ultimately lead to end-stage renal disease requiring kidney transplant or dialysis.Anemia is a common complication in patients with CKD,with increasing incidence as the disease progresses.Erythropoiesis-stimulating agents (ESAs) are the mainstay of renal anemia management but cardiovascular safety concerns have limited their use.Hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitors are a new class of oral drugs for the treatment of renal anemia.More and more attention has been paid to the research on HIF-PHD inhibitors at home and abroad but limited systematic reviews are reported.In this paper,the action mechanism of HIF-PHD inhibitors and their research advances are reviewed,with focus on the drugs under clinical investigation.
Keywords：chronic kidney diseaseanemiahypoxia-inducible factorprolyl hydroxylasehypoxia-inducible factor prolyl hydroxylase inhibitor
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：5( 2701-2705 )